Efficacy of Quadruplet Therapy with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone as Initial Treatment for High-Risk Multiple Myeloma Patients in China: Findings from a Multi-Center Real-World Study - Poll - MDSpire

Efficacy of Quadruplet Therapy with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone as Initial Treatment for High-Risk Multiple Myeloma Patients in China: Findings from a Multi-Center Real-World Study

  • By

  • Lili Cheng

  • Dong Liang

  • Jing Jia

  • Runfeng Zhang

  • Yang Yang

  • Peng Liu

  • Hongli Sun

  • Xiaoqi Qin

  • Yanping Ma

  • Yin Wu

  • Hua Wang

  • Junling Zhuang

  • March 10, 2026

  • 0 min

Share

Original Source(s)

Efficacy of Quadruplet Therapy with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone as Initial Treatment for High-Risk Multiple Myeloma Patients in China: Findings from a Multi-Center Real-World Study

  • by Lili Cheng, Dong Liang, Jing Jia, Runfeng Zhang, Yang Yang, Peng Liu, Hongli Sun, Xiaoqi Qin, Yanping Ma, Yin Wu, Hua Wang, Junling Zhuang

  • March 10, 2026

Related Content

This Week’s Biopharma News: Amgen Deepens US Manufacturing Push

The company adds $300 million to its Puerto Rico biologics site as Pfizer reports Phase 3 myeloma data, J&J advances a dual-pathway IBD antibody, and BioNTech streamlines production

  • May 12, 2026

  • 7 min
Short-term cardiotoxicity and early echocardiographic changes following autologous hematopoietic stem cell transplantation: a single-center retrospective analysis

Enterocolitis Associated with Immune Effector Cells Following BCMA-Targeted CAR T-Cell Therapy: Findings from a Multicenter Case Series